Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Another look at silent circulation of poliovirus in small populations.

Kalkowska DA, Duintjer Tebbens RJ, Thompson KM.

Infect Dis Model. 2018 Jun 9;3:107-117. doi: 10.1016/j.idm.2018.06.001. eCollection 2018.

2.

Characterising the costs of the Global Polio Laboratory Network: a survey-based analysis.

Duintjer Tebbens RJ, Diop OM, Pallansch MA, Oberste MS, Thompson KM.

BMJ Open. 2019 Jan 21;9(1):e023290. doi: 10.1136/bmjopen-2018-023290.

3.

Global certification of wild poliovirus eradication: insights from modelling hard-to-reach subpopulations and confidence about the absence of transmission.

Duintjer Tebbens RJ, Kalkowska DA, Thompson KM.

BMJ Open. 2019 Jan 15;9(1):e023938. doi: 10.1136/bmjopen-2018-023938.

4.

Modeling Undetected Live Poliovirus Circulation After Apparent Interruption of Transmission: Pakistan and Afghanistan.

Kalkowska DA, Duintjer Tebbens RJ, Pallansch MA, Thompson KM.

Risk Anal. 2019 Feb;39(2):402-413. doi: 10.1111/risa.13214. Epub 2018 Oct 8.

PMID:
30296340
5.

Evaluation of Proactive and Reactive Strategies for Polio Eradication Activities in Pakistan and Afghanistan.

Duintjer Tebbens RJ, Thompson KM.

Risk Anal. 2019 Feb;39(2):389-401. doi: 10.1111/risa.13194. Epub 2018 Sep 21.

PMID:
30239026
6.

Environmental Surveillance System Characteristics and Impacts on Confidence About No Undetected Serotype 1 Wild Poliovirus Circulation.

Kalkowska DA, Duintjer Tebbens RJ, Thompson KM.

Risk Anal. 2019 Feb;39(2):414-425. doi: 10.1111/risa.13193. Epub 2018 Sep 21.

PMID:
30239023
7.

Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine.

Duintjer Tebbens RJ, Thompson KM.

Expert Rev Vaccines. 2018 Aug;17(8):739-751. doi: 10.1080/14760584.2018.1506333. Epub 2018 Aug 9. Review.

8.

Planning for globally coordinated cessation of bivalent oral poliovirus vaccine: risks of non-synchronous cessation and unauthorized oral poliovirus vaccine use.

Duintjer Tebbens RJ, Hampton LM, Thompson KM.

BMC Infect Dis. 2018 Apr 10;18(1):165. doi: 10.1186/s12879-018-3074-0.

9.

Modeling Poliovirus Transmission in Pakistan and Afghanistan to Inform Vaccination Strategies in Undervaccinated Subpopulations.

Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Ehrhardt DT, Farag NH, Hadler SC, Hampton LM, Martinez M, Wassilak SGF, Thompson KM.

Risk Anal. 2018 Aug;38(8):1701-1717. doi: 10.1111/risa.12962. Epub 2018 Jan 3.

PMID:
29314143
10.

Lessons From Globally Coordinated Cessation of Serotype 2 Oral Poliovirus Vaccine for the Remaining Serotypes.

Thompson KM, Duintjer Tebbens RJ.

J Infect Dis. 2017 Jul 1;216(suppl_1):S168-S175. doi: 10.1093/infdis/jix128.

11.

Lessons From the Polio Endgame: Overcoming the Failure to Vaccinate and the Role of Subpopulations in Maintaining Transmission.

Thompson KM, Duintjer Tebbens RJ.

J Infect Dis. 2017 Jul 1;216(suppl_1):S176-S182. doi: 10.1093/infdis/jix108.

12.

Insights from a Systematic Search for Information on Designs, Costs, and Effectiveness of Poliovirus Environmental Surveillance Systems.

Duintjer Tebbens RJ, Zimmermann M, Pallansch MA, Thompson KM.

Food Environ Virol. 2017 Dec;9(4):361-382. doi: 10.1007/s12560-017-9314-4. Epub 2017 Jul 7. Review.

PMID:
28687986
13.

Modeling the costs and benefits of temporary recommendations for poliovirus exporting countries to vaccinate international travelers.

Duintjer Tebbens RJ, Thompson KM.

Vaccine. 2017 Jul 5;35(31):3823-3833. doi: 10.1016/j.vaccine.2017.05.090. Epub 2017 Jun 9.

14.

Poliovirus vaccination during the endgame: insights from integrated modeling.

Duintjer Tebbens RJ, Thompson KM.

Expert Rev Vaccines. 2017 Jun;16(6):577-586. doi: 10.1080/14760584.2017.1322514. Epub 2017 May 9. Review.

PMID:
28437234
15.

Costs and Benefits of Including Inactivated in Addition to Oral Poliovirus Vaccine in Outbreak Response After Cessation of Oral Poliovirus Vaccine Use.

Duintjer Tebbens RJ, Thompson KM.

MDM Policy Pract. 2017 Mar 1;2(1):2381468317697002. doi: 10.1177/2381468317697002. eCollection 2017 Jan-Jun.

16.

The potential benefits of a new poliovirus vaccine for long-term poliovirus risk management.

Duintjer Tebbens RJ, Thompson KM.

Future Microbiol. 2016 Dec;11:1549-1561. Epub 2016 Nov 10.

17.
18.

Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use.

Duintjer Tebbens RJ, Hampton LM, Thompson KM.

BMC Infect Dis. 2016 Jun 1;16:237. doi: 10.1186/s12879-016-1537-8.

19.

Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation.

Duintjer Tebbens RJ, Hampton LM, Thompson KM.

BMC Infect Dis. 2016 May 26;16:231. doi: 10.1186/s12879-016-1536-9.

20.

Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame.

Duintjer Tebbens RJ, Pallansch MA, Wassilak SG, Cochi SL, Thompson KM.

BMC Infect Dis. 2016 Mar 24;16:137. doi: 10.1186/s12879-016-1465-7.

21.

Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs.

Duintjer Tebbens RJ, Thompson KM.

BMC Infect Dis. 2015 Sep 24;15:390. doi: 10.1186/s12879-015-1114-6.

22.

An economic analysis of poliovirus risk management policy options for 2013-2052.

Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SG, Thompson KM.

BMC Infect Dis. 2015 Sep 24;15:389. doi: 10.1186/s12879-015-1112-8.

23.

The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission.

Thompson KM, Duintjer Tebbens RJ.

BMC Infect Dis. 2015 Sep 17;15:376. doi: 10.1186/s12879-015-1116-4.

24.

Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs.

Duintjer Tebbens RJ, Pallansch MA, Thompson KM.

BMC Infect Dis. 2015 Sep 17;15:379. doi: 10.1186/s12879-015-1115-5.

25.
26.

Combinations of Quality and Frequency of Immunization Activities to Stop and Prevent Poliovirus Transmission in the High-Risk Area of Northwest Nigeria.

Duintjer Tebbens RJ, Pallansch MA, Wassilak SG, Cochi SL, Thompson KM.

PLoS One. 2015 Jun 11;10(6):e0130123. doi: 10.1371/journal.pone.0130123. eCollection 2015.

27.

Modeling undetected live poliovirus circulation after apparent interruption of transmission: implications for surveillance and vaccination.

Kalkowska DA, Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SG, Thompson KM.

BMC Infect Dis. 2015 Feb 18;15:66. doi: 10.1186/s12879-015-0791-5.

28.

Managing population immunity to reduce or eliminate the risks of circulation following the importation of polioviruses.

Thompson KM, Kalkowska DA, Duintjer Tebbens RJ.

Vaccine. 2015 Mar 24;33(13):1568-77. doi: 10.1016/j.vaccine.2015.02.013. Epub 2015 Feb 18.

29.

Modeling options to manage type 1 wild poliovirus imported into Israel in 2013.

Kalkowska DA, Duintjer Tebbens RJ, Grotto I, Shulman LM, Anis E, Wassilak SG, Pallansch MA, Thompson KM.

J Infect Dis. 2015 Jun 1;211(11):1800-12. doi: 10.1093/infdis/jiu674. Epub 2014 Dec 10.

PMID:
25505296
30.

Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation.

Duintjer Tebbens RJ, Thompson KM.

J Infect Dis. 2014 Nov 1;210 Suppl 1:S485-97. doi: 10.1093/infdis/jit838.

PMID:
25316871
31.

Modeling the dynamics of oral poliovirus vaccine cessation.

Thompson KM, Duintjer Tebbens RJ.

J Infect Dis. 2014 Nov 1;210 Suppl 1:S475-84. doi: 10.1093/infdis/jit845.

PMID:
25316870
32.

Individual-based modeling of potential poliovirus transmission in connected religious communities in North America with low uptake of vaccination.

Kisjes KH, Duintjer Tebbens RJ, Wallace GS, Pallansch MA, Cochi SL, Wassilak SG, Thompson KM.

J Infect Dis. 2014 Nov 1;210 Suppl 1:S424-33. doi: 10.1093/infdis/jit843.

PMID:
25316864
33.

Modeling strategies to increase population immunity and prevent poliovirus transmission in the high-risk area of northwest Nigeria.

Kalkowska DA, Duintjer Tebbens RJ, Thompson KM.

J Infect Dis. 2014 Nov 1;210 Suppl 1:S412-23. doi: 10.1093/infdis/jit834.

PMID:
25316863
34.

Modeling strategies to increase population immunity and prevent poliovirus transmission in 2 high-risk areas in northern India.

Kalkowska DA, Duintjer Tebbens RJ, Thompson KM.

J Infect Dis. 2014 Nov 1;210 Suppl 1:S398-411. doi: 10.1093/infdis/jit844.

PMID:
25316861
35.

Framework for Optimal Global Vaccine Stockpile Design for Vaccine-Preventable Diseases: Application to Measles and Cholera Vaccines as Contrasting Examples.

Thompson KM, Duintjer Tebbens RJ.

Risk Anal. 2016 Jul;36(7):1487-509. doi: 10.1111/risa.12265. Epub 2014 Aug 11.

PMID:
25109229
36.

The potential impact of expanding target age groups for polio immunization campaigns.

Duintjer Tebbens RJ, Kalkowska DA, Wassilak SG, Pallansch MA, Cochi SL, Thompson KM.

BMC Infect Dis. 2014 Jan 29;14:45. doi: 10.1186/1471-2334-14-45.

37.

National choices related to inactivated poliovirus vaccine, innovation and the endgame of global polio eradication.

Thompson KM, Duintjer Tebbens RJ.

Expert Rev Vaccines. 2014 Feb;13(2):221-34. doi: 10.1586/14760584.2014.864563. Epub 2013 Dec 4. Review.

PMID:
24308581
38.

Review and assessment of poliovirus immunity and transmission: synthesis of knowledge gaps and identification of research needs.

Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, Modlin JF, Patriarca PA, Sutter RW, Wright PF, Wassilak SG, Cochi SL, Kim JH, Thompson KM.

Risk Anal. 2013 Apr;33(4):606-46. doi: 10.1111/risa.12031. Epub 2013 Mar 28. Review.

PMID:
23550968
39.

Characterizing poliovirus transmission and evolution: insights from modeling experiences with wild and vaccine-related polioviruses.

Duintjer Tebbens RJ, Pallansch MA, Kalkowska DA, Wassilak SG, Cochi SL, Thompson KM.

Risk Anal. 2013 Apr;33(4):703-49. doi: 10.1111/risa.12044. Epub 2013 Mar 22.

PMID:
23521018
40.

Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs).

Duintjer Tebbens RJ, Pallansch MA, Kim JH, Burns CC, Kew OM, Oberste MS, Diop OM, Wassilak SG, Cochi SL, Thompson KM.

Risk Anal. 2013 Apr;33(4):680-702. doi: 10.1111/risa.12022. Epub 2013 Mar 7.

PMID:
23470192
41.

Preeradication vaccine policy options for poliovirus infection and disease control.

Thompson KM, Pallansch MA, Duintjer Tebbens RJ, Wassilak SG, Kim JH, Cochi SL.

Risk Anal. 2013 Apr;33(4):516-43. doi: 10.1111/risa.12019. Epub 2013 Mar 5.

PMID:
23461599
42.

Costs of illness due to cholera, costs of immunization and cost-effectiveness of an oral cholera mass vaccination campaign in Zanzibar.

Schaetti C, Weiss MG, Ali SM, Chaignat CL, Khatib AM, Reyburn R, Duintjer Tebbens RJ, Hutubessy R.

PLoS Negl Trop Dis. 2012;6(10):e1844. doi: 10.1371/journal.pntd.0001844. Epub 2012 Oct 4.

43.

Expert review on poliovirus immunity and transmission.

Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, Modlin JF, Patriarca PA, Sutter RW, Wright PF, Wassilak SG, Cochi SL, Kim JH, Thompson KM.

Risk Anal. 2013 Apr;33(4):544-605. doi: 10.1111/j.1539-6924.2012.01864.x. Epub 2012 Jul 15. Review.

PMID:
22804479
44.

The probability of undetected wild poliovirus circulation after apparent global interruption of transmission.

Kalkowska DA, Duintjer Tebbens RJ, Thompson KM.

Am J Epidemiol. 2012 May 1;175(9):936-49. doi: 10.1093/aje/kwr399. Epub 2012 Mar 29.

PMID:
22459121
45.

Economic analysis of the global polio eradication initiative.

Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SG, Linkins J, Sutter RW, Aylward RB, Thompson KM.

Vaccine. 2010 Dec 16;29(2):334-43. doi: 10.1016/j.vaccine.2010.10.026. Epub 2010 Oct 26.

PMID:
21029809
46.

Development of an individual-based model for polioviruses: implications of the selection of network type and outcome metrics.

Rahmandad H, Hu K, Duintjer Tebbens RJ, Thompson KM.

Epidemiol Infect. 2011 Jun;139(6):836-48. doi: 10.1017/S0950268810001676. Epub 2010 Jul 12.

PMID:
20619075
47.
48.

Uncertainty and sensitivity analyses of a decision analytic model for posteradication polio risk management.

Duintjer Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Bruce Aylward R, Watkins M, Gary H, Alexander J, Jafari H, Cochi SL, Thompson KM.

Risk Anal. 2008 Aug;28(4):855-76. doi: 10.1111/j.1539-6924.2008.01078.x. Epub 2008 Jul 4.

PMID:
18627544
49.

Uncertainty and sensitivity analyses of a dynamic economic evaluation model for vaccination programs.

Duintjer Tebbens RJ, Thompson KM, Hunink MG, Mazzuchi TA, Lewandowski D, Kurowicka D, Cooke RM.

Med Decis Making. 2008 Mar-Apr;28(2):182-200. doi: 10.1177/0272989X07311752. Epub 2008 Mar 18.

PMID:
18349438
50.

Development and consideration of global policies for managing the future risks of poliovirus outbreaks: insights and lessons learned through modeling.

Thompson KM, Duintjer Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Aylward RB, Watkins M, Gary H, Alexander JP, Venczel L, Johnson D, Cáceres VM, Sangrujee N, Jafari H, Cochi SL.

Risk Anal. 2006 Dec;26(6):1571-80.

PMID:
17184398

Supplemental Content

Loading ...
Support Center